Dr. Shahab Mehdizadeh, MD

Dr. Mehdizadeh practices at Alpha Surgery Center LLC in Sherman Oaks, California.

Dr. Mehdizadeh's NPI, 1790715241, was assigned on July 3, 2006. Dr. Mehdizadeh graduated from University of Rochester School of Medicine and Dentistry in 2000. Dr. Mehdizadeh holds California license A76490.

Dr. Mehdizadeh's primary practice is Alpha Surgery Center LLC, at 4910 N Van Nuys Blvd, Sherman Oaks, CA 91403 in Los Angeles County. The practice phone is (818) 986-9099.

Dr. Mehdizadeh's primary practice is Alpha Surgery Center LLC in Sherman Oaks, California. Dr. Mehdizadeh is also affiliated with Cedars-Sinai Medical Center. Dmand AI also links Dr. Mehdizadeh to 1 more physician office and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mehdizadeh practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Mehdizadeh's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Mehdizadeh is licensed in California.

Dmand AI lists acid reflux, acute gastroduodenitis, bile duct problems, chronic indigestion, chronic inflammatory bowel disease (IBD), cirrhosis of the liver, colonoscopy and gastroduodenitis among the conditions Dr. Mehdizadeh treats.

CMS data shows 6,082 Medicare services from Dr. Mehdizadeh across 21 procedure codes in 2024, for 772 Medicare patients. Medicare paid $478,482 for them.

CMS counts 772 Medicare patients who saw Dr. Mehdizadeh in 2024. The largest group is 65 to 74, with 322 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 45% are also on Medicaid. Their average risk score is 2.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mehdizadeh's median patient age at 70, with 53% women.

In 2024, Dr. Mehdizadeh wrote 1,589 Medicare Part D claims for 410 patients. 71% of them were for generic drugs. CMS names the drug for 1,300 of them, across 23 drugs with 11 or more claims each, at $605,659 in total drug cost. In 2023, CMS named 1,360 claims across 36 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Mehdizadeh for performance year 2024, reported individually. Dr. Mehdizadeh accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mehdizadeh as offering telehealth. CMS counts 311 procedures of colonoscopy by Dr. Mehdizadeh, more than 97% of the clinicians it reports for that procedure.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 3 papers to Dr. Mehdizadeh in 2008. The most frequent topics are Chromosome Mapping. Dr. Mehdizadeh's most frequent co-authors are Kenneth F. Binmoeller, MD, Ann M. Chen, MD and Robert V. Farese, MD.

CMS Open Payments shows 393 general payments to Dr. Mehdizadeh from 30 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 81% of the total. Abbvie Inc. paid the most, $204,090.

Dmand AI lists 1 award for Dr. Mehdizadeh, most recently CMS Stage 1 EHR in 2013.

Dr. Mehdizadeh graduated from University of Rochester School of Medicine and Dentistry in 2000.

Dr. Mehdizadeh is in network with 3 carriers, including Excellus BlueCross BlueShield, Blue Cross Blue Shield of Michigan and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.